Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoto T Ueno

Showing results (1-10 of 386) with videos related to

Pageof 39
Sort By:
JAMA Oncology|June 25, 2026
Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast CancerNaoto T Ueno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatmentsKazutaka Nakayama, Naoto T Ueno
Cancer Biomarkers : Section a of Disease Markers|June 6, 2013
Biomarker discordance during tumor progressionNaoki Niikura, Naoto T Ueno
Cancer Biomarkers : Section a of Disease Markers|June 6, 2013
Change in HER2 status during breast tumor progressionNaoki Niikura, Naoto T Ueno
The Oncologist|March 24, 2018
The Emerging Impact of Social Media on Cancer Patient Education in JapanYuya Sasaki, Naoto T Ueno
Cancer|May 27, 2010
Targeted therapy in inflammatory breast cancerHideko Yamauchi, Naoto T Ueno
British Journal of Cancer|March 15, 2017
Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''Takeo Fujii, Naoto T Ueno
Journal of Cancer|September 16, 2010
The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast CancerNaoki Niikura, Naoto T Ueno
Chinese Clinical Oncology|December 21, 2021
"Why and What" for the optimal management of inflammatory breast cancerNaoto T Ueno, Angela Alexander
The Lancet. Oncology|February 20, 2025
Navigating the androgen receptor landscape in triple-negative breast cancerNithya Sridhar, Naoto T Ueno
Pageof 39

Showing results (1-10 of 386) with videos related to

Sort By:
Pageof 39
JAMA Oncology|June 25, 2026
Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast CancerNaoto T Ueno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatmentsKazutaka Nakayama, Naoto T Ueno
Cancer Biomarkers : Section a of Disease Markers|June 6, 2013
Biomarker discordance during tumor progressionNaoki Niikura, Naoto T Ueno
Cancer Biomarkers : Section a of Disease Markers|June 6, 2013
Change in HER2 status during breast tumor progressionNaoki Niikura, Naoto T Ueno
The Oncologist|March 24, 2018
The Emerging Impact of Social Media on Cancer Patient Education in JapanYuya Sasaki, Naoto T Ueno
Cancer|May 27, 2010
Targeted therapy in inflammatory breast cancerHideko Yamauchi, Naoto T Ueno
British Journal of Cancer|March 15, 2017
Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''Takeo Fujii, Naoto T Ueno
Journal of Cancer|September 16, 2010
The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast CancerNaoki Niikura, Naoto T Ueno
Chinese Clinical Oncology|December 21, 2021
"Why and What" for the optimal management of inflammatory breast cancerNaoto T Ueno, Angela Alexander
The Lancet. Oncology|February 20, 2025
Navigating the androgen receptor landscape in triple-negative breast cancerNithya Sridhar, Naoto T Ueno
Pageof 39